Pricing and Market Access Strategy for New Immunology Therapy
- Developed pricing strategy for a therapy entering a crowded market.
-
Required a clear view of how the evidence package, expected clinical outcomes, and HTA assessments would shape
pricing flexibility and access.
-
Pricing complexity was heightened by multiple doses, titration patterns, and indications across multiple
therapeutic areas.
- Assessed clinical and HTA outcomes for price and access implications.
-
Built a revenue model to define price thresholds by market, balancing broad coverage and minimal restrictions
with WAC.
- Estimated required rebate levels to support target access outcomes.
-
Developed a competitive landscape of comparator products, including utilization, market share, and cost dynamics,
to model expected share capture.
-
Designed a complex utilization-based rebate approach to account for varying doses, titration patterns, and
cross-indication pricing dynamics.
- Defined a market-specific pricing strategy to optimize access while preserving value.
- Quantified rebate expectations and pricing thresholds needed to support payer coverage goals.
- Built a more realistic view of competitive share capture in a crowded market.
- Supported decision-making for a complex, multi-indication pricing and contracting strategy.
